CTOs on the Move

NeuBase Therapeutics

www.neubasetherapeutics.com

 
NeuBase is developing ultra precision genetic medicines targeting rare, monogenic diseases, therapeutic candidates for the treatment of myotonic dystrophy type 1 (DM1), Huntington`s disease (HD), and cancer-driving point mutations in KRAS G12V and G12D, which are involved in many tumor types and have historically been “undruggable.” for which there are no approved therapies, as well as more common genetic disorders, including cancers that are resistant to current therapeutic approaches. NeuBase`s pipeline includes
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Anthony Rossomando
Chief Technology Officer Profile

Similar Companies

Navicent Health

Navicent Health was incorporated on November 17, 1994, as a nonprofit corporation whose primary purpose is to coordinate the Medical Center, Navicent Health and other affiliated entities in their mission of providing a comprehensive continuum of high quality, reasonably priced healthcare services to the region. Navicent Health has 830 beds for medical, surgical, rehabilitation and hospice purposes. The Medical Center, Navicent Health – a nationally recognized tertiary teaching hospital and the primary teaching hospital for Mercer University School of Medicine - includes but is not limited to: •Peyton Anderson Cancer Center, Navicent Health, a provider of comprehensive cancer care. Our services cover the continuum of cancer care, from screening and diagnosis through treatment and into survivorship. •Emergency Center, Navicent Health provides access to our Level 1 Trauma Center and includes helipad capability. The Emergency Center, along with our three urgent care locations, treat over 120,000 visitors per year. •Family Birth Center, Navicent Health has spacious labor and delivery suites, focuses on providing a family-friendly and family-centered environment for expectant mothers and their babies, and specializes in care for difficult pregnancies. •Heart Center, Navicent Health provides a full range of services for the prevention, diagnosis and treatment of cardiovascular disease, including congestive heart failure. •Rehabilitation Hospital, Navicent Health is the oldest and most experienced medical rehabilitation provider in central Georgia providing comprehensive services to help patients achieve their highest level of mobility and independence. •Beverly Knight Olson Children`s Hospital, Navicent Health, the region`s only dedicated pediatric hospital Navicent Health is the region`s leading provider of a comprehensive continuum of services. Whatever your healthcare needs, Navicent Health is here to assist you and your loved ones.

Accord Healthcare

Accord Healthcare is a global provider of generic and specialty pharmaceuticals. Our focus on a rapidly expanding portfolio of affordable generic…

CareFirst Urgent Care

Quality medical attention and care when you need it. All locations offer PCR, Rapid, Antinbody, and Rapid Antibody testing. Open 8am to 8pm, 7 days a week!

Alvogen

Alvogen is a multinational, privately owned pharmaceuticals company focused on developing, manufacturing and distributing generic, brand, over-the-counter brands (OTC) and biosimilar products. With more than 200 pharmaceutical projects in development and registration, the group`s product portfolio consists of a broad range of leading molecules for the treatment of conditions in the fields of: oncology, cardiology, respiratory, neurology and gastroenterology. Alvogen has commercial operations in over 30 countries with 2,000 employees. North America is Alvogen`s single largest market and other key markets include: South-Korea, Romania, Bulgaria, Hungary, Taiwan, Russia and China.

RedHill Biopharma

RedHill Biopharma, established in 2009, is a publicly traded (NASDAQ: RDHL) (Tel-Aviv Stock Exchange: RDHL) specialty biopharmaceutical company, headquartered in Israel, primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases, including cancer. RedHill’s pipeline includes several drug candidates in advanced clinical development stages addressing clear medical needs and aiming to relieve suffering and save lives. RedHill’s drugs are largely de-risked and are potentially of lower cost and faster to market than new chemical entities under development. RedHill’s products are based on several technology platforms and address several disease targets, thus providing for risk diversification. RedHill’s U.S. commercial operations, headquartered in Raleigh, NC, include a gastrointestinal-focused sales force of approximately 40 sales representatives promoting two speciality gastrointestinal products in select U.S. territories. RedHill’s experienced management team, board of directors and advisory board, based in Israel, the US, Canada and Europe, comes with a successful track record of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise. '